Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) - Overview
Hospital Acquired Pneumonia (HAP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
AstraZeneca Plc
Bioversys AG
Centauri Therapeutics Ltd
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
Evaxion Biotech ApS
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
briva Therapeutics Plc
Nosopharm SAS
Polyphor AG
Sealife PHARMA GMBH
Shionogi & Co Ltd
Spero Therapeutics Inc
Tetraphase Pharmaceuticals Inc
VetoRx Pharmaceuticals Inc
Wockhardt Ltd
Hospital Acquired Pneumonia (HAP) - Drug Profiles
(avibactam + aztreom) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(avibactam sodium + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + VNRX-5133) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + zidebactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cilastatin sodium + imipenem + relebactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbekacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BV-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefiderocol sulfate tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eravacycline dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVXB-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gremubamab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iclaprim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levodifloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
murepavadin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cubactam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOSO-2G - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Paecin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
panobacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-7001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharides for Hospital Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qn-2251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections and Ventilator Associated Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvratoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telavancin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Oct 15, 2019: New study reveals superiority of Vibativ over Vancomycin in select patients with Bacterial Pneumonia
Oct 15, 2019: New study reveals superiority of Vibativ over Vancomycin in select patients with Bacterial Pneumonia
Oct 02, 2019: Shionogi reports positive results from Cefiderocol phase III study in adults with pneumonia caused by gram-negative pathogens
Oct 02, 2019: Shionogi reports positive results from Cefiderocol phase III study in adults with pneumonia caused by gram-negative pathogens
Sep 30, 2019: Pivotal RESTORE-IMI 2 phase 3 study of Merck’s RECARBRIO (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) met primary endpoint
relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) met primary endpoint
Sep 26, 2019: Shionogi to present data of cefiderocol at IDWeek 2019
Sep 26, 2019: Shionogi to present data of cefiderocol at IDWeek 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

 

List of Tables


Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Bioversys AG, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Nosopharm SAS, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2019
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2019
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2019